SCHEMBL740898

SCHEMBL740898

O=C(c1ccc2[nH]cnc2c1)N1CCC2(CCCC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.48
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 2/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
ENPP2 Q13822 1/20 0.46
ATXN2 Q99700 1/20 0.46
LMNA P02545 2/20 0.45
GPR183 P32249 1/20 0.44
ACACB O00763 2/20 0.44
USP2 O75604 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13373550 0.87 HPGD (0.58) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL1855882 0.85 HPGD (0.61) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL1855879 0.85 HPGD (0.61) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL29565081 0.85 HPGD (0.61) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL14559795 0.82 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL22999769 0.81 KDM4E (0.55) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL3153203 0.81 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL1063453 0.81 L3MBTL1 (0.57) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL13646643 0.81 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB
SCHEMBL111568 0.81 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1KDM4EHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US claimed
EP-1802623-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS Novo Nordisk A/S (DK) 2007-07-04 EP claimed
WO-2006040329-A1 1 IBETA- HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS NOVO NORDISK A/S (DK) 2006-04-20 WO claimed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
EP-1802623-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS Novo Nordisk A/S (DK) 2007-07-04 EP disclosed
WO-2006040329-A1 1 IBETA- HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS NOVO NORDISK A/S (DK) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds HSD11B1, HSD3B1, HSD17B1 SMN1; SMN2 2622/4885ALDH1A1 53/4885KDM4E 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.